HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) CME: Take the course for this article: Patient-reported Outcomes in Cancer: A Review of Recent Research and Policy... Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lipscomb, J. Articles by Snyder, C. F. Search for Related Content PubMed PubMed Citation Articles by Lipscomb, J. Articles by Snyder, C. F.

Patient-reported Outcomes in Cancer

A Review of Recent Research and Policy Initiatives

Dr. Lipscomb is Professor, Rollins School of Public Health, Emory University, Atlanta, GA.
Dr. Gotay is Professor, Cancer Research Center of Hawai'i, University of Hawai'i, Honolulu, HI.
Dr. Snyder is Assistant Professor of Medicine, Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD.

This article is available online at http://CAonline.AmCancerSoc.org
To earn free CME credit for successfully completing the online quiz based on this article, go to http://CME.AmCancerSoc.org.
Disclosure: Dr. Lipscomb's work on this article was partially supported by a grant from the Georgia Cancer Coalition's Distinguished Cancer Clinicians and Scientists program.

There is growing recognition that patient-reported outcome (PRO) measures—encompassing, for example, health-related quality of life—can complement traditional biomedical outcome measures (eg, survival, disease-free survival) in conveying important information for cancer care decision making. This paper provides an integrated review and interpretation of how PROs have been defined, measured, and used in a range of recent cancer research and policy initiatives. We focus, in turn, on the role of PRO measurement in the evaluation and approval of cancer therapies, the assessment of cancer care in the community, patient-provider decision making in clinical oncology practice, and population surveillance of cancer patients and survivors. The paper concludes with a discussion of future challenges and opportunities in PRO measure development and application, given the advancing state of the science in cancer outcomes measurement and the evolving needs of cancer decision makers at all levels.